Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16807
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGoh, Su Kah-
dc.contributor.authorGold, Grace-
dc.contributor.authorChristophi, Christopher-
dc.contributor.authorMuralidharan, Vijayaragavan-
dc.date2017-08-13-
dc.date.accessioned2017-08-18T00:41:45Z-
dc.date.available2017-08-18T00:41:45Z-
dc.date.issued2017-08-13-
dc.identifier.citationANZ Journal of Surgery 2017; 87(12): 987-992en_US
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/16807-
dc.description.abstractThe optimal management of oncological conditions is reflected by the careful interpretation of investigations for screening, diagnosis, staging, prognostication and surveillance. Serum tumour markers are examples of commonly requested tests in conjunction with other imaging and endoscopic tests that are used to help clinicians to stratify therapeutic decisions. Serum carbohydrate antigen 19-9 (CA19-9) is a key biomarker for pancreatic cancers. Although this biomarker is considered clinically useful and informative, clinicians are often challenged by the accurate interpretation of elevated serum CA19-9 levels. Recognizing the pitfalls of normal and abnormal serum CA19-9 concentrations will facilitate its appropriate use. In this review, we appraised the biomarker, serum CA19-9, and highlighted the clinical utility and limitations of serum CA19-9 in the investigation and management of pancreatic cancers.en_US
dc.subjectCA19-9en_US
dc.subjectClinical utilityen_US
dc.subjectPancreatic canceren_US
dc.subjectPrognostic valueen_US
dc.subjectSerum biomarkeren_US
dc.titleSerum carbohydrate antigen 19-9 in pancreatic adenocarcinoma: a mini review for surgeonsen_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleANZ Journal of Surgeryen_US
dc.identifier.affiliationHepato-Pancreato-Biliary and Transplant Unit, Austin Health, Heidelberg, Victoria, Australiaen_US
dc.identifier.affiliationDepartment of Surgery, The University of Melbourne, Melbourne, Victoria, Australiaen_US
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/28803454en_US
dc.identifier.doi10.1111/ans.14131en_US
dc.type.contentTexten_US
dc.identifier.orcid0000-0002-6684-2521en
dc.identifier.orcid0000-0001-8247-8937en
dc.identifier.orcid0000-0002-4001-4912en
dc.type.austinJournal Articleen_US
local.name.researcherChristophi, Christopher
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairetypeJournal Article-
crisitem.author.deptSurgery (University of Melbourne)-
crisitem.author.deptHepatopancreatobiliary Surgery-
crisitem.author.deptSurgery-
crisitem.author.deptHepatopancreatobiliary Surgery-
crisitem.author.deptSurgery (University of Melbourne)-
crisitem.author.deptHepatopancreatobiliary Surgery-
crisitem.author.deptSurgery-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

20
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.